LianBio (LIANY)

OTCMKTS · Delayed Price · Currency is USD
0.4100
+0.0029 (0.71%)
Jun 27, 2025, 3:59 PM EDT
32.75%
Market Cap 44.35M
Revenue (ttm) n/a
Net Income (ttm) -87.98M
Shares Out 108.17M
EPS (ttm) -0.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 72,250
Average Volume 377,454
Open 0.4100
Previous Close 0.4071
Day's Range 0.4078 - 0.4195
52-Week Range 0.1743 - 0.4235
Beta 0.46
RSI 73.16
Earnings Date Aug 13, 2025

About LianBio

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatme... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 163
Stock Exchange OTCMKTS
Ticker Symbol LIANY
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.